For the twelve months ended Sep 30, 2026, Beta Bionics Inc. reported $127.27M of revenue and -$83.12M of net income.
BBNX revenue was $35.51M in fiscal Q3 2026 (ended Sep 30, 2026), up 30.3% from a year earlier and up 10.9% from the prior quarter. For the full fiscal 2025 it was $100.25M, up 53.9% from fiscal 2024.
BBNX net income was -$24.35M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$14.21M a year earlier. For the full fiscal 2025 it was -$73.20M, compared with -$54.76M in fiscal 2024.
BBNX diluted EPS was -$0.52 in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$0.33 a year earlier. For the full fiscal 2025 it was -$1.81.
BBNX free cash flow was -$14.56M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$10.01M a year earlier. For the full fiscal 2025 it was -$56.22M, compared with -$51.67M in fiscal 2024.
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
|---|---|---|---|
| Revenue | $100.25M | $65.12M | $11.99M |
| Cost of revenue | $44.71M | $29.24M | $5.69M |
| Gross profit | $55.54M | $35.89M | $6.31M |
| Research and development | $34.79M | $26.18M | $17.94M |
| Selling, general and admin | $31.02M | $17.87M | $12.22M |
| Operating income | -$71.68M | -$45.25M | -$35.85M |
| Income tax | $0 | $0 | - |
| Net income | -$73.20M | -$54.76M | -$44.10M |
| EPS, basic | -$1.81 | -$8.60 | -$8.31 |
| EPS, diluted | -$1.81 | -$8.60 | -$8.31 |
| Diluted shares | 40.5M | 6.4M | 5.3M |
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
|---|---|---|---|
| Cash and equivalents | $31.58M | $30.53M | $26.67M |
| Short-term investments | $187.55M | $73.14M | $70.18M |
| Receivables | $17.12M | $12.00M | $4.45M |
| Inventory | $21.72M | $13.32M | $1.25M |
| Current assets | $267.90M | $132.92M | $103.62M |
| Total assets | $328.74M | $149.65M | $110.04M |
| Current liabilities | $30.92M | $21.15M | $10.61M |
| Total liabilities | $41.13M | $73.63M | $51.43M |
| Shareholders' equity | $287.61M | -$245.36M | -$203.10M |
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
|---|---|---|---|
| Operating cash flow | -$50.92M | -$48.27M | -$32.45M |
| Capital expenditures | $5.30M | $3.40M | $402.0K |
| Free cash flow | -$56.22M | -$51.67M | -$32.85M |
| Investing cash flow | -$162.81M | -$3.48M | -$69.69M |
| Financing cash flow | $214.87M | $55.62M | $101.03M |
| Stock-based compensation | $16.38M | $6.38M | $5.66M |
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
|---|---|---|---|
| Revenue growth, YoY | 53.9% | 442.9% | - |
| Gross margin | 55.4% | 55.1% | 52.6% |
| Operating margin | -71.5% | -69.5% | -298.9% |
| Net margin | -73.0% | -84.1% | -367.6% |
| Free cash flow margin | -56.1% | -79.3% | -273.8% |
| Return on equity | -25.5% | - | - |
| Return on assets | -22.3% | -36.6% | -40.1% |
| Current ratio | 8.66 | 6.29 | 9.77 |
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $35.51M | $32.01M | $27.63M | $32.12M | $27.25M | $23.24M | $17.64M | $20.44M | $16.70M | $15.05M | $12.93M |
| Cost of revenue | $15.17M | $13.11M | $11.19M | $13.18M | $12.13M | $10.73M | $8.67M | $8.75M | $7.79M | $6.96M | $5.73M |
| Gross profit | $20.33M | $18.90M | $16.44M | $18.94M | $15.12M | $12.50M | $8.97M | $11.69M | $8.91M | $8.08M | $7.20M |
| Research and development | $11.97M | $10.24M | $10.36M | $10.13M | $8.20M | $8.87M | $7.59M | $9.21M | $5.14M | $6.35M | $5.48M |
| Selling, general and admin | $9.84M | $9.60M | $9.62M | $8.60M | $7.92M | $7.88M | $6.62M | $4.71M | $5.11M | $4.54M | $3.51M |
| Operating income | -$26.61M | -$25.58M | -$24.27M | -$16.12M | -$17.04M | -$19.87M | -$18.64M | -$13.04M | -$10.98M | -$11.78M | -$9.45M |
| Net income | -$24.35M | -$23.40M | -$21.89M | -$13.47M | -$14.21M | -$16.87M | -$28.66M | -$18.11M | -$9.74M | -$14.46M | -$12.45M |
| EPS, basic | -$0.52 | -$0.53 | -$0.49 | - | -$0.33 | -$0.39 | -$0.93 | -$2.70 | -$1.46 | -$2.37 | -$2.07 |
| EPS, diluted | -$0.52 | -$0.53 | -$0.49 | - | -$0.33 | -$0.39 | -$0.93 | -$2.70 | -$1.46 | -$2.37 | -$2.07 |
| Diluted shares | 46.5M | 44.5M | 44.4M | - | 43.6M | 43.4M | 30.7M | - | 6.7M | 6.1M | 6.0M |
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $81.55M | $44.32M | $30.21M | $31.58M | $38.48M | $35.08M | $42.45M | $30.53M | $17.48M | $13.03M | $22.07M |
| Short-term investments | $158.65M | $136.17M | $169.31M | $187.55M | $190.20M | $214.65M | $189.02M | $73.14M | - | - | - |
| Receivables | $20.67M | $18.05M | $15.75M | $17.12M | $11.54M | $11.39M | $9.06M | $12.00M | - | - | - |
| Inventory | $22.97M | $23.92M | $23.73M | $21.72M | $20.37M | $17.32M | $15.73M | $13.32M | - | - | - |
| Current assets | $292.95M | $231.03M | $247.99M | $267.90M | $270.03M | $286.07M | $261.92M | $132.92M | - | - | - |
| Total assets | $443.76M | $292.39M | $304.42M | $328.74M | $330.05M | $329.97M | $338.02M | $149.65M | - | - | - |
| Current liabilities | $32.84M | $26.02M | $23.19M | $30.92M | $25.39M | $19.49M | $16.49M | $21.15M | - | - | - |
| Total liabilities | $42.38M | $36.02M | $33.17M | $41.13M | $35.29M | $28.34M | $24.27M | $73.63M | - | - | - |
| Shareholders' equity | $401.38M | $256.37M | $271.25M | $287.61M | $294.76M | $301.63M | $313.75M | -$245.36M | -$228.85M | -$221.21M | -$214.32M |
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$12.29M | -$14.62M | -$23.83M | -$8.63M | -$8.73M | -$13.59M | -$19.98M | -$14.28M | -$9.61M | -$12.24M | -$12.14M |
| Capital expenditures | $2.27M | $1.04M | $1.38M | $1.90M | $1.28M | $1.78M | $333.0K | $561.0K | $1.92M | $507.0K | $406.0K |
| Free cash flow | -$14.56M | -$15.66M | -$25.21M | -$10.53M | -$10.01M | -$15.37M | -$20.31M | -$14.84M | -$11.53M | -$12.74M | -$12.55M |
| Investing cash flow | -$114.08M | $26.93M | $21.84M | $658.0K | $9.49M | $6.17M | -$179.12M | -$29.66M | $15.24M | $3.30M | $7.64M |
| Financing cash flow | $163.60M | $1.80M | $623.0K | $1.06M | $2.65M | $42.0K | $211.12M | $56.89M | -$1.18M | -$107.0K | $6.0K |
| Stock-based compensation | $6.71M | $7.02M | $5.41M | $4.30M | $4.48M | $4.80M | $2.80M | $1.55M | $1.98M | $1.50M | $1.36M |
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | 30.3% | 37.8% | 56.6% | 57.1% | 63.1% | 54.4% | 36.4% | - | - | - | - |
| Gross margin | 57.3% | 59.0% | 59.5% | 59.0% | 55.5% | 53.8% | 50.9% | 57.2% | 53.4% | 53.7% | 55.7% |
| Operating margin | -74.9% | -79.9% | -87.9% | -50.2% | -62.5% | -85.5% | -105.7% | -63.8% | -65.7% | -78.3% | -73.1% |
| Net margin | -68.6% | -73.1% | -79.3% | -41.9% | -52.1% | -72.6% | -162.5% | -88.6% | -58.3% | -96.1% | -96.3% |
| Free cash flow margin | -41.0% | -48.9% | -91.3% | -32.8% | -36.7% | -66.2% | -115.1% | -72.6% | -69.0% | -84.7% | -97.0% |
| Current ratio | 8.92 | 8.88 | 10.69 | 8.66 | 10.64 | 14.68 | 15.88 | 6.29 | - | - | - |
Source: XBRL data Beta Bionics Inc. files with the SEC, latest filing dated Oct 27, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| BBNX | $127.27M | +43.7% | -$83.12M | -65.3% | $898.1M |
| SYK | $26.30B | +7.9% | $3.62B | 13.8% | $123.45B |
| MMM | $25.25B | +1.7% | $3.54B | 14.0% | $97.85B |
| BSX | $21.07B | +8.9% | $3.50B | 16.6% | $64.78B |
| BDX | $23.25B | +17.4% | $941.00M | 4.0% | $57.91B |
| MDLN | $30.68B | - | $683.00M | 2.2% | $53.81B |
| RMD | $5.73B | +9.0% | $1.59B | 27.8% | $32.93B |
| DXCM | $5.10B | +13.0% | $991.00M | 19.4% | $29.81B |
| WST | $3.40B | +12.6% | $638.90M | 18.8% | $28.74B |